Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Bonding over biosimilars
August 2016
SHARING OPTIONS:

GENEVA—A new service agreement is underway between life-sciences company Selexis SA and biosimilar developer Turgut Ilaclari A.S. granting Turgut access to Selexis’ SUREtechnology Platform and SURE CHO-M Cell Line for developing biosimilar products to treat inflammatory diseases, some cancers and a pair of rare diseases. The companies have also inked two commercial license agreements in conjunction with the first two Turgut products using the SURE CHO-M Cell lines. Selexis will be entitled to milestone payments and royalties if the product candidates meet certain clinical development stages and significant commercial sales levels.
 
“Selexis’ industrial cell line technology is an important component of our biotechnology platform established for the development and production of high-quality biosimilar monoclonal antibodies to improve human health in Turkey and globally,” remarked Dr. Serdar Alpan, Turgut Biotechnology Group Leader.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.